Cancer Immunology Immunotherapy · 2018 · 179 citations · 26 references
Life SciencesImmunologyPharmacologyCell SignalingMetabolic RegulationSignal TransductionAutonomic Nervous System ResponsesImmune Cell MetabolismImmune SignalingLymphoid Organ PhysiologyStress-immune InteractionsAdrenergic Receptor AgonistsAdrenergic Receptor SignalingAdrenergic SignalingAutonomic Nervous System EffectsBeta-adrenergic AgentsCd8 T Cell ActivationCellular Metabolic ReprogrammingHelper T Cell Effector Function
Primary and secondary lymphoid organs are heavily innervated by the autonomic nervous system. Norepinephrine, the primary neurotransmitter secreted by post-ganglionic sympathetic neurons, binds to and activates β-adrenergic receptors expressed on the surface of immune cells and regulates the functions of these cells. While it is known that both activated and memory CD8 + T-cells primarily express the β2-adrenergic receptor (β2-AR) and that signaling through this receptor can inhibit CD8 + T-cell effector function, the mechanism(s) underlying this suppression is not understood. Under normal activation conditions, T-cells increase glucose uptake and undergo metabolic reprogramming. In this study, we show that treatment of murine CD8 + T-cells with the pan β-AR agonist isoproterenol (ISO) was associated with a reduced expression of glucose transporter 1 following activation, as well as decreased glucose uptake and glycolysis compared to CD8 + T-cells activated in the absence of ISO. The effect of ISO was specifically dependent upon β2-AR, since it was not seen in adrb2 −/− CD8 + T-cells and was blocked by the β-AR antagonist propranolol. In addition, we found that mitochondrial function in CD8 + T-cells was also impaired by β2-AR signaling. This study demonstrates that one mechanism by which β2-AR signaling can inhibit CD8 + T-cell activation is by suppressing the required metabolic reprogramming events which accompany activation of these immune cells and thus reveals a new mechanism by which adrenergic stress can suppress the effector activity of immune cells.
26
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih‐Hao Chang, Jing Qiu, David O’Sullivan et al. · Cell · 2015 · 3.2K citations · Full text
Medicine, Cancer Biology, Oncology +16
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chih‐Hao Chang, Jonathan D. Curtis, Leonard B. Maggi et al. · Cell · 2013 · 2.2K citations · Full text
The CD28 Signaling Pathway Regulates Glucose Metabolism
Kenneth A. Frauwirth, James L. Riley, Marian H. Harris et al. · Immunity · 2002 · 1.4K citations · Full text